Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-13 7:02 pm Unchanged | 2024-02-13 | 13G | Syros Pharmaceuticals, Inc. SYRS | Ally Bridge MedAlpha Master Fund L.P. | 0 0.000% | 0 (Unchanged) | Filing |
| 2023-01-27 6:01 pm Purchase | 2022-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS | Ally Bridge MedAlpha Master Fund L.P. | 1,439,379 6.900% | 1,046,327 (+266.21%) | Filing History |
| 2022-02-11 4:19 pm Sale | 2021-12-31 | 13G | Viridian Therapeutics, Inc. VRDN | Ally Bridge MedAlpha Master Fund L.P. | 604,774 2.800% | -325,205 (-34.97%) | Filing History |
| 2022-02-11 4:17 pm Sale | 2021-12-31 | 13G | Cogent Biosciences, Inc. COGT | Ally Bridge MedAlpha Master Fund L.P. | 1,501,591 3.800% | -121,000 (-7.46%) | Filing History |
| 2022-02-11 4:17 pm Purchase | 2021-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS | Ally Bridge MedAlpha Master Fund L.P. | 393,052 6.300% | 89,740 (+29.59%) | Filing History |